You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
凱普生物(300639.SZ):子公司獲得歐洲發明專利證書
格隆匯 02-13 19:03

格隆匯2月13日丨凱普生物(300639.SZ)公佈,近日,公司全資子公司廣州凱普醫藥科技有限公司(“凱普醫藥”)、廣州凱普生物科技有限公司(“廣州凱普”)獲歐洲專利局頒發的發明專利證書,為CHLOROQUINE GEL AND PREPARATION METHOD AND APPLICATION THEREOF (一種氯喹凝膠及其製備方法和應用)。

公司已運用本發明技術開發藥品“磷酸氯喹凝膠”,目前該藥品正在開展II期有效性及安全性評價的臨牀試驗,試驗進展順利。“磷酸氯喹凝膠”適應症為皮膚外用治療HPV病毒感染引起的各種皮膚疣、外生殖器及肛周尖鋭濕疣,為國內外尚未批准的新適應症。通過皮膚外用給藥,減少全身藥物暴露量,提高藥品的有效性和安全性。

上述發明專利的取得將有利於公司充分發揮自主知識產權優勢,加強自主知識產權的國際保護並進一步完善公司的知識產權保護體系,促進公司技術創新,增強公司的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account